| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13280* | 2021 |
| NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ... Nature medicine 21 (8), 914-921, 2015 | 992 | 2015 |
| Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients T Condamine, GA Dominguez, JI Youn, AV Kossenkov, S Mony, ... Science immunology 1 (2), aaf8943-aaf8943, 2016 | 699 | 2016 |
| B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma AD Cohen, AL Garfall, EA Stadtmauer, JJ Melenhorst, SF Lacey, ... The Journal of clinical investigation 129 (6), 2210-2221, 2019 | 665 | 2019 |
| Chimeric antigen receptor T cells against CD19 for multiple myeloma AL Garfall, MV Maus, WT Hwang, SF Lacey, YD Mahnke, JJ Melenhorst, ... New England Journal of Medicine 373 (11), 1040-1047, 2015 | 654 | 2015 |
| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 617 | 2019 |
| Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma DT Vogl, EA Stadtmauer, KS Tan, DF Heitjan, LE Davis, L Pontiggia, ... Autophagy 10 (8), 1380-1390, 2014 | 388 | 2014 |
| Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102 … A Krishnan, MC Pasquini, B Logan, EA Stadtmauer, DH Vesole, E Alyea, ... The lancet oncology 12 (13), 1195-1203, 2011 | 337 | 2011 |
| Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial EA Stadtmauer, MC Pasquini, B Blackwell, P Hari, A Bashey, S Devine, ... Journal of clinical oncology 37 (7), 589-597, 2019 | 255 | 2019 |
| Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma DT Vogl, N Raje, S Jagannath, P Richardson, P Hari, R Orlowski, ... Clinical Cancer Research 23 (13), 3307-3315, 2017 | 246 | 2017 |
| Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma JJ Shah, EA Stadtmauer, R Abonour, AD Cohen, WI Bensinger, ... Blood, The Journal of the American Society of Hematology 126 (20), 2284-2290, 2015 | 241 | 2015 |
| Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis AJ Waxman, S Clasen, WT Hwang, A Garfall, DT Vogl, J Carver, ... JAMA oncology 4 (3), e174519-e174519, 2018 | 222 | 2018 |
| Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial BS Abella, EL Jolkovsky, BT Biney, JE Uspal, MC Hyman, I Frank, ... JAMA internal medicine 181 (2), 195-202, 2021 | 218 | 2021 |
| Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study A D'Souza, A Dispenzieri, B Wirk, MJ Zhang, J Huang, MA Gertz, RA Kyle, ... Journal of Clinical Oncology 33 (32), 3741-3749, 2015 | 212 | 2015 |
| Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study SF Huntington, BM Weiss, DT Vogl, AD Cohen, AL Garfall, PA Mangan, ... The Lancet Haematology 2 (10), e408-e416, 2015 | 206 | 2015 |
| Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma AL Garfall, EA Stadtmauer, WT Hwang, SF Lacey, JJ Melenhorst, ... JCI insight 3 (8), 2018 | 202 | 2018 |
| EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial DE Tsai, L Douglas, C Andreadis, DT Vogl, S Arnoldi, R Kotloff, ... American journal of transplantation 8 (5), 1016-1024, 2008 | 182 | 2008 |
| Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma AP Rapoport, NA Aqui, EA Stadtmauer, DT Vogl, HB Fang, L Cai, ... Blood, The Journal of the American Society of Hematology 117 (3), 788-797, 2011 | 179 | 2011 |
| Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma DT Vogl, D Dingli, RF Cornell, CA Huff, S Jagannath, D Bhutani, J Zonder, ... Journal of clinical oncology 36 (9), 859-866, 2018 | 166 | 2018 |
| Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma RF Cornell, B Ky, BM Weiss, CN Dahm, DK Gupta, L Du, JR Carver, ... Journal of clinical oncology 37 (22), 1946-1955, 2019 | 163 | 2019 |
